Recruiting

Evaluation of the Efficacy of Biobran (Rice Bran Arabinoxylan) in Supporting Breast Cancer Chemotherapy

This study aims to evaluate the potential supportive effects of rice bran arabinoxylan compound (Biobran) in patients with breast cancer receiving paclitaxel and doxorubicin chemotherapy. The study will assess chemotherapy-related side effects, quality of life, tumor size, tumor antigens, and routine blood test parameters over 24 weeks of treatment.

ClinicalTrials.gov IDNCT07503496

PhaseNA

Enrollment96

SponsorChina Medical University Hospital

Age20 Years

SexFEMALE

I'm interested View official listing

Conditions studied

Breast Cancer Stages I, Breast Cancer Stages II, Breast Cancer Stage III

About this study

Interventions

Dietary Supplement: Biobran supplementation — 3 g Biobran per day for 24 weeks

Primary outcomes

Change from baseline in the mean quality of life score at 12 weeks (Baseline and at 6、12、18、24 weeks after chemotherapy)

Eligibility information

Inclusion Criteria: * Breast cancer stage I-III Exclusion Criteria: * pregnant, lactation, breast recurrence, mental disease, autoimmune disease over hte past 5 years, people who take plant or fungal polysaccharide health supplements

Study locations

China Medical University Hospital, Taichung, 406040 Taiwan
China Medical University, Taichung, 406040 Taiwan

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.